Hormonal
In people with type 2 diabetes, objectively assessed moderate-to-vigorous physical activity (MVPA) is inversely associated with systemic inflammatory markers IL-6, IL-1ra, and MCP-1, with the association being largely mediated by adiposity (BMI).
For people with Type 2 Diabetes, engaging in moderate-to-vigorous physical activity (like brisk walking) for just 10-minute increments daily is associated with lower levels of key inflammatory markers (IL-6, IL-1ra). While weight loss (BMI) plays a significant role in this benefit, the act of moving itself also reduces inflammation through non-weight-related mechanisms. Focus on consistent, moderate-intensity movement rather than just weight loss metrics.
We observed inverse associations between moderate-to-vigorous physical activity (per 10 min) with plasma interleukin-6 (B=−0.035, 95% CI −0.056 to −0.015), interleukin-1ra (B=−0.033, 95% CI −0.051 to −0.015), and monocyte chemotactic protein-1 (B=−0.011, 95% CI −0.021 to 0.000)... These associations largely persisted in multivariable adjusted models, although body mass index considerably attenuated the effect estimate.
Why this rating
Cross-sectional design prevents causal inference, but uses objective measurement (accelerometry) and rigorous statistical adjustment.
Source
Objectively assessed physical activity, adiposity, and inflammatory markers in people with type 2 diabetes
Mark Hamer et al. · BMJ Open Diabetes Research & Care · 2014
DOI 10.1136/bmjdrc-2014-000030
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →